New to MyHealth?
Manage Your Care From Anywhere.
Access your health information from any device with MyHealth. You can message your clinic, view lab results, schedule an appointment, and pay your bill.
ALREADY HAVE AN ACCESS CODE?
DON'T HAVE AN ACCESS CODE?
NEED MORE DETAILS?
MyHealth for Mobile
Post-transplantation cyclophosphamide to facilitate HLA-haploidentical hematopoietic cell transplantation: Mechanisms and results
Post-transplantation cyclophosphamide to facilitate HLA-haploidentical hematopoietic cell transplantation: Mechanisms and results SEMINARS IN HEMATOLOGY Elmariah, H., Fuchs, E. J. 2019; 56 (3): 183-189Abstract
Allogeneic blood or marrow transplantation (BMT) is a curative therapy for a number of high-risk hematologic malignancies. Historically, only patients with a human leukocyte antigen (HLA)-matched sibling or unrelated donor were able to receive this therapy, thus excluding many potential transplant recipients. In recent years, partially mismatched related donor, or human leukocyte antigen-haploidentical (haplo) BMT has expanded the donor pool to nearly every patient in need of a transplant, particularly when using post-transplantation cyclophosphamide to promote immune tolerance and prevent graft-versus-host disease. With now over 15 years of clinical experience using this platform, long terms outcomes are well understood. We review the clinical literature and highlight the advantages and disadvantages of haplo BMT with post-transplantation cyclophosphamide.
View details for DOI 10.1053/j.seminhematol.2018.09.002
View details for Web of Science ID 000473118600003
View details for PubMedID 31202428
View details for PubMedCentralID PMC9229262